Dependence of the microRNA profile in cutaneous melanoma on clinical and morphological characteristics of the tumor


Cite item

Full Text

Abstract

Melanoma is an aggressive skin cancer that is characterized by rapid growth and high invasion. Today extensive studies of melanomagenesis allow to subdivide this tumor into subtypes in accordance to molecular, genetic and biochemical characteristics in addition to standard histological classification for developing personalized approaches of treatment. One ofsuch molecular peculiarities is the expression profile of microRNAs in tumor cells alterations of which were shown during tumor progression. The aim of this study was to identify the correlation between the levels ofmicroRNA in melanoma cells, and the clinical and morphological characteristics of the disease. The comparative study of microRNAs expression profiles in melanoma is made by gender, age ofpatients, tumor Breslow’s thickness and histological subtypes. It was shown that the gender and age ofpatients have no effect on the expression of microRNA in melanoma. No correlation between the microRNA levels and tumor Breslow’s thickness was revealed. But it was observed a significant alteration between the microRNA profiles in the different histological melanoma subtypes. The significant change in the profile of microRNAs for superficial-spreading melanomas compared to other subtypes was shown that was associated with the processes of tumors development, as well as ErbB-, MAPK-, TGF-β-signaling pathways. Further study of the molecularfeatures of the superficial-spreading melanoma in combination with other characteristics might be a new step towards personalized medicine.

About the authors

A. V Komina

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Krasnoyarsk, 660022, Russian Federation

N. V Palkina

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Krasnoyarsk, 660022, Russian Federation

M. B Aksenenko

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Krasnoyarsk, 660022, Russian Federation

Tatyana G. Ruksha

Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky

Email: tatyana_ruksha@mail.ru
Dr. Sci. Med., Head of Department of pathophysiology Krasnoyarsk, 660022, Russian Federation

References

  1. Имянитов Е.Н. Эпидемиология и биология опухолей кожи. Практическая онкология. 2012; 13(2): 61-8.
  2. Liu V., Mihm M.C. Pathology of malignant melanoma. Surg. Clin. North Am. 2003; 83(1): 31-60.
  3. Greenwald H.S., Friedman E.B., Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2012; 22(1): 1-8.
  4. Chan E., Patel R., Nallur S., Ratner E., Bacchiocchi A., Hoyt K., et al. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011; 10(11): 1845-52.
  5. Joosse A., de Vries E., Eckel R., Nijsten T., Eggermont A.M., Hölzel D., et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J. Invest. Dermatol. 2011; 131(3): 719-26.
  6. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS ONE. 2012; 7(3): e32955.
  7. Kaur A., Webster M.R., Marchbank K., Behera R., Ndoye A., Kugel C.H., et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016; 532(7598): 250-4.
  8. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-97.
  9. Ha T.Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw. 2011; 11(3): 135-54.
  10. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043): 834-8.
  11. Швецова Ю.И., Палкина Н.В., Аксененко М.Б., Рукша Т.Г. Изменения экспрессии микроРНК при меланоцитарных новообразованиях кожи. Российский журнал кожных и венерических болезней. 2015; 18(3): 6-9.
  12. Xu Y., Brenn T., Brown E.R., Doherty V., Melton D.W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br. J. Cancer. 2012; 106(3): 553-61. doi: 10.1038/bjc.2011.568.
  13. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B. 1995; 57(1): 289-300.
  14. Vlachos I.S., Kostoulas N., Vergoulis T., Georgakilas G., Reczko M., Maragkakis M., et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012. http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath (дата обращения 04.07.2016).
  15. Сlark Jr. W.H., From L., Bernardino E.A., Mihm M.C. Histogenesis and biological behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29(3): 705-27.
  16. Crowson A.N., Magro C.M., Mihm M.C. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Modern Pathol. 2006; 19(Suppl. 2): S71-87.
  17. Mueller D.W., Rehli M., Bosserhoff A.K. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 2009; 129(7): 1740-51.
  18. Jönsson G., Busch Ch., Knappskog S., Geisler J., Miletic H., Ringnér M., et al. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clin. Cancer Res. 2010; 16(13): 3356-67.
  19. Scolyera R.A., Longa G.V., Thompsona J.F. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol. Oncol. 2011; 5(2): 124-36.
  20. Smoller B.R. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Modern Pathol. 2006: 19(Suppl. 2): S34-40.
  21. Barnhill R.L., Mihm M.C. The histopathology of cutaneous malignant melanoma.Seminars Diagn. Pathol. 1993; 10(1): 47-75.
  22. Poliseno L., Haimovic A., Segura M.F., Hanniford D., Christos P.J., Darvishian F., et al. Histology-specific microRNA alterations in melanoma. J. Invest. Dermatol. 2012; 132(7): 1860-8.
  23. Feinmesser M., Veltman V., Morgenstern S., Tobar A., Gutman H., Kaganovsky E., et al. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study. Am. J. Dermatopathol. 2010; 32(7): 665-75.
  24. Van Belle P., Rodeck U., Nuamah I., Halpern A.C., Elder D.E. Melanoma-associated expression of transforming growth factor β isoforms. Am. J. Pathol. 1996; 148(6): 1887-94.
  25. Pardali K., Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta. 2007; 1775(1): 21-62.
  26. Caramuta S., Egyházi S., Rodolfo M., Witten D., Hansson J., Larsson C., et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 2010; 130(8): 2062-70.
  27. Sand M., Skrygan M., Sand D., Georgas D., Gambichler Th., Hahn S.A., et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013; 351(1): 85-98.
  28. Segura M.F., Greenwald H.S., Hanniford D., Osman I., Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis. 2012; 33(10): 1823-32.
  29. Lin R.L., Wang T.J., Joyce C.J., Mihm M.C., Murphy G.F., Lian C.G., Lin J.Y. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched super ficial spreading melanomas. Melanoma Res. 2016; 26(5): 524-7. doi: 10.1097/CMR.0000000000000253.
  30. Lauss M., Nsengimana J., Staaf J., Newton-Bishop J., Jönsson G. Consensus of melanoma gene expression subtypes converges on biological entities. J. Invest. Dermatol. 2016. pii: S0022-202X(16)31363-X. doi: 10.1016/j.jid.2016.05.119.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies